CK HMW + p63 + AMACR (RM)

Prostate cancer stained with CK HMW + p63 + AMACR (RM)

High molecular weight cytokeratins are expressed in a variety of normal and neoplastic epithelial tissues (1). In prostate, CK HMW [34βE12] has been shown to be a useful marker of basal cells of normal glands and prostatic intraepithelial neoplasia (PIN), a precursor lesion to prostatic adenocarcinoma; whereas invasive prostatic adenocarcinoma typically lacks a basal cell layer (2-4).

p63, a homolog of the tumor suppressor p53, has been identified in proliferating basal cells in the epithelial layers of a variety of tissues, including epidermis, cervix, urothelium and prostate (5). p63 was detected in nuclei of the basal epithelium in normal prostate glands; however, it was not expressed in malignant tumors of the prostate (6).

α-Methylacyl coenzyme A racemase (AMACR), also known as P504S, is a peroxisomal and mitochondrial enzyme that plays a role in bile acid synthesis and β-oxidation of branched chain fatty acids (7). AMACR was initially identified from a cDNA library as a gene that is overexpressed in human prostate cancer; with little or no expression in normal prostate (8,9). In immunohistochemistry, AMACR has been shown to be a specific marker of prostatic adenocarcinoma (8-11). Additionally, prostate glands involved in PIN have been found to express AMACR, whereas AMACR was nearly undetectable in benign glands (11,12).

Studies have shown that combinations of CK HMW [34βE12], p63, and/or AMACR may be useful in the evaluation of normal prostate glands, PIN and prostatic adenocarcinoma (13,14).
U.S. Patent 8,603,765 and patents pending

CK HMW + p63, 2X

Prostate cancer stained with CK HMW + p63

High molecular weight cytokeratins are expressed in a variety of normal and neoplastic epithelial tissues (1). In prostate, CK HMW [34βE12] has been shown to be a useful marker of basal cells of normal glands and prostatic intraepithelial neoplasia (PIN), a precursor lesion to prostatic adenocarcinoma; whereas invasive prostatic adenocarcinoma typically lacks a basal cell layer (2,3).

p63, a homolog of the tumor suppressor p53, has been identified in proliferating basal cells in the epithelial layers of a variety of tissues, including epidermis, cervix, urothelium and prostate (4). p63 was detected in nuclei of the basal epithelium in normal prostate glands; however, it was not expressed in malignant tumors of the prostate (5).

Studies have shown that combinations of CK HMW [34βE12] and p63 may be useful in the evaluation of normal prostate glands, PIN and prostatic adenocarcinoma (6,7). CK HMW + p63, 2X is provided as a concentrated antibody cocktail suitable for the addition of other primary antibodies desired by the user. A 2-fold dilution of CK HMW + p63, 2X is intended to create a ready-to-use antibody cocktail for use on the ONCORE Automated Slide Stainer.

p63

Prostate tissue stained with p63 antibody

p53 homologue p63 encodes for different isotypes able to either transactivate p53 reporter genes (TAp63) or act as p53-dominant-negatives. p63 is detected in prostatic basal cells in normal prostate; however, it is negative in malignant tumors of the prostate gland. Thus p63 antibody may be a valuable tool in the differential diagnosis of benign and malignant tumors of prostate gland and can be used in a panel of antibodies such as HMW CK [34ßE12], PSA and PSAP. p63 may play a significant role in prostate development by maintaining a prostate stem cell population. Striated muscle staining may be observed with p63.

p63, 2X (Lung)

Lung SqCC stained with p63, 2X

p63 has been shown to be a sensitive marker for lung squamous cell carcinomas (SqCC), with reported sensitivities of 80-100% (1-6). Specificity for lung SqCC, versus lung adenocarcinoma (LADC), has been reported to be approximately 70-90%, as positive staining with p63 has been typically observed in 10-30% of LADC (1-6). Cocktails of p63 with complementary markers for lung SqCC have also proven useful. A cocktail of p63 + TRIM29 demonstrated a 94.7% sensitivity for lung SqCC and 100% specificity versus LADC, in cases where Napsin A and TTF-1 were both negative (2-7). Similarly, the combination of p63 + CK5 identified 87% of cases of lung SqCC, with 94% specificity (8).

p63, 3X (Breast)

Breast cancer stained with p63 antibody

p63, 3X (Breast) [4A4] is comprised of a mouse monoclonal anti-p63 antibody. p63 is a transcription factor present in the nuclei of myoepithelial cells of normal breast ducts (1,2). p63 has routinely been used in a panel of IHC markers to complement morphological evaluation in the assessment of breast lesions, due to the differential expression of the luminal vs. basal and myoepithelial markers (1-6). Cases of usual ductal hyperplasia (UDH) have been associated with expression of the basal cell markers, intermixed with cells expressing the keratins of luminal cells (1-3,7-11). Most cases of atypical ductal hyperplasia (ADH) and low grade ductal carcinoma in situ (LG DCIS) were negative for basal markers and exhibited an immunophenotype indicative of luminal cells (1,5-9). Additionally, the basal phenotype has been shown to be characterized by luminal expression of the basal and myoepithelial markers, using a cocktail of CK5, CK14 and p63 (12-14).
IHC, using CK5, CK14, p63, CK7 and CK18 antibodies, evaluated in combination with hematoxylin and eosin (H&E), has been shown to significantly increase interobserver agreement amongst pathologists, compared to H&E alone (15).

p63, 3X (Breast)

Breast cancer stained with p63 antibody

p63, 3X (Breast) Antibody [4A4] is comprised of a mouse monoclonal anti-p63 antibody. p63 is a transcription factor present in the nuclei of myoepithelial cells of normal breast ducts (1,2). p63 has routinely been used in a panel of IHC markers to complement morphological evaluation in the assessment of breast lesions, due to the differential expression of the luminal vs. basal and myoepithelial markers (1-6). Cases of usual ductal hyperplasia (UDH) have been associated with expression of the basal cell markers, intermixed with cells expressing the keratins of luminal cells (1-3,7-11). Most cases of atypical ductal hyperplasia (ADH) and low grade ductal carcinoma in situ (LG DCIS) were negative for basal markers and exhibited an immunophenotype indicative of luminal cells (1,5-9). Additionally, the basal phenotype has been shown to be characterized by luminal expression of the basal and myoepithelial markers, using a cocktail of CK5, CK14 and p63 (12-14).

IHC, using CK5, CK14, p63, CK7 and CK18 antibodies, evaluated in combination with hematoxylin and eosin (H&E), has been shown to significantly increase interobserver agreement amongst pathologists, compared to H&E alone (15).

 

p63, 3X (Breast)

Breast cancer stained with p63, 3X

p63, 3X (Breast) Antibody [4A4] is comprised of a mouse monoclonal anti-p63 antibody. p63 is a transcription factor present in the nuclei of myoepithelial cells of normal breast ducts
(1,2). p63 has routinely been used in a panel of IHC markers to complement morphological evaluation in the assessment of breast lesions, due to the differential expression of the luminal vs. basal and myoepithelial markers (1-6). Cases of usual ductal hyperplasia (UDH) have been associated with expression of the basal cell markers, intermixed with cells expressing the keratins of luminal cells (1-3,7-11). Most cases of atypical ductal hyperplasia (ADH) and low grade ductal carcinoma in situ (LG DCIS) were negative for basal markers and exhibited an immunophenotype indicative of luminal cells (1,5-9). Additionally, the basal phenotype has been shown to be characterized by luminal expression of the basal and myoepithelial markers, using a cocktail of CK5, CK14 and p63 (12-14).

IHC, using CK5, CK14, p63, CK7 and CK18 antibodies, evaluated in combination with hematoxylin and eosin (H&E), has been shown to significantly increase interobserver agreement amongst pathologists, compared to H&E alone (15).

p63, 3X (Prostate)

Prostate tissue stained with p63 prostate antibody, 3X

p63, a homolog of the tumor suppressor p53, has been identified in proliferating basal cells in the epithelial layers of a variety of tissues, including epidermis, cervix, urothelium and prostate. p63 was detected in nuclei of the basal epithelium in normal prostate glands; and prostatic intraepithelial neoplasia (PIN); however, it was not expressed in malignant tumors of the prostate.

p63-2X

Prostate cancer stained with p63 [4a4] antibody, 2X

p53 homologue p63 encodes for different isotypes able to either transactivate p53 reporter genes (TAp63) or act as p53-dominant-negatives. Studies have shown that p63 [4a4] antibody detection by IHC has clinical utility in the evaluation of lung, prostate, cervical and other types of cancer in formalin fixed, paraffin-embedded (FFPE) human tissues. A cocktail of p63 and TRIM29 can also be utilized for lung SqCC and studies have shown that when p63 and/or TRIM29 is expressed in lung SqCC, a 95.4% sensitivity and 100% specificity was achieved, if Napsin A and TTF-1 were both negative in the same case.